Spruce Biosciences GAAP EPS of -$8.94 Misses by $1.01

Spruce Biosciences press release (SPRB): Q1 GAAP EPS of -$8.94 misses by $1.01. - Cash and cash equivalents as of March 31, 2026 were $54.1 million, compared to $48.9 million as of December 31, 2025. Spruce believes that its cash and cash equivalents as of March 31, 2026,

Spruce Biosciences press release (SPRB): Q1 GAAP EPS of -$8.94 misses by $1.01. – Cash and cash equivalents as of March 31, 2026 were $54.1 million, compared to $48.9 million as of December 31, 2025.

Spruce believes that its cash and cash equivalents as of March 31, 2026, together

Leave a Reply

Your email address will not be published. Required fields are marked *